Trevi Therapeutics Inc. (TRVI)
NASDAQ: TRVI
· Real-Time Price · USD
10.63
0.01 (0.09%)
At close: Oct 16, 2025, 3:59 PM
10.86
2.16%
After-hours: Oct 16, 2025, 07:48 PM EDT
0.09% (1D)
| Bid | 10.4 |
| Market Cap | 1.29B |
| Revenue (ttm) | 146K |
| Net Income (ttm) | -47.3M |
| EPS (ttm) | -0.42 |
| PE Ratio (ttm) | -25.31 |
| Forward PE | -20.38 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 11.29 |
| Volume | 2,332,282 |
| Avg. Volume (20D) | 2,217,053 |
| Open | 10.72 |
| Previous Close | 10.62 |
| Day's Range | 10.47 - 11.11 |
| 52-Week Range | 2.36 - 11.11 |
| Beta | 0.74 |
| Ex-Dividend Date | n/a |
About TRVI
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TRVI
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TRVI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
-5.85%
Trevi Therapeutics shares are trading lower after ...
Unlock content with
Pro Subscription
4 months ago
-2.92%
TRVI stock has given up its prior gain. Trevi Therapeutics shares were trading higher after the company announced positive topline results from its Phase 2b CORAL trial of Haduvio.
2 months ago · seekingalpha.com
Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call TranscriptTrevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants g - Corporate Participant e - Corporate Participant Farrell Simon - Chief Commer...